IP Library Granted Patent US 7,064,244
Granted Patent B2
US 7,064,244 · App. 10/078,958 · Granted Jun 20, 2006

Transgenic mammals having human Ig loci including plural V

Assignee: Abgenix, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,064,244
App. No.
10/078,958
Granted
Jun 20, 2006
Kind
B2
Abstract

The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (V H and Vκ) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.

Claims (15)

1. A transgenic mouse whose genome comprises a fragment of human chromosome 14 from the five most proximal V H gene segments, continuing through the D segment genes, the J segment genes and the constant region genes through Cδ of the human immunoglobulin heavy chain locus, wherein said fragment does not contain a Cγ gene, and wherein said fragment is operably linked to a human Cγ gene selected from the group consisting of: a human Cγ1 gene, a human Cγ3 gene, and a human Cγ4 gene

said transgenic mouse producing fully human antibodies having IgG1, IgG3, or IgG4 heavy chains, respectively, specific for a desired antigen when immunized with said desired antigen.

2. The transgenic mouse according to claim 1 , wherein said mouse further comprises a fragment of human chromosome 2 comprising human V κ , human J κ and human C κ gene segments of an immunoglobulin kappa light chain locus

said transgenic mouse producing fully human antibodies having IgG1, IgG3, or IgG4 heavy chains, respectively, specific for a desired antigen when immunized with said desired antigen.

3. The transgenic mouse according to claim 2 , wherein said fragment of human chromosome 2 extends from the three most proximal V κ gene segments, continuing through the J κ and C κ gene segments, through the human kappa deleting element.

4. The transgenic mouse according to any one of claims 1 – 3 , wherein said mouse further comprises:

a) inactivated endogenous immunoglobulin heavy chain loci in which all of the J segment genes are deleted to prevent rearrangement and to prevent formation of a transcript of a rearranged locus and the expression of an endogenous immunoglobulin heavy chain; and

b) inactivated endogenous immunoglobulin light chain loci in which the C κ gene is deleted to prevent rearrangement and to prevent formation of a transcript of a rearranged locus and the expression of an endogenous immunoglobulin light chain;

wherein said transgenic mouse lacks expression of endogenous immunoglobulin heavy and kappa light chains.

5. A method for producing a fully human IgG antibody specific for a desired antigen, comprising:

(a) immunizing a transgenic mouse according to any one of claims 1 – 3 with said desired antigen; and

(b) recovering the antibody.

6. A method for producing a fully human IgG antibody specific for a desired antigen, comprising:

(a) immunizing a transgenic mouse according to claim 4 with said desired antigen; and

(b) recovering the antibody.

Continuity (2)
Continuation 0875962000 · Dec 3, 1996
Related Publication 20030070185A1 · Apr 10, 2003